Recombinant vascular endothelial growth factor secreted from tissue-engineered bioartificial muscles promotes localized angiogenesis.
- 31 July 2001
- journal article
- other
- Published by Wolters Kluwer Health in Circulation
- Vol. 104 (5) , 594-599
- https://doi.org/10.1161/hc3101.092215
Abstract
Background Therapeutic angiogenesis by the administration of recombinant vascular endothelial growth factor (rVEGF) is a novel strategy for the treatment of ischemic disorders. rVEGF has been delivered as a protein, by plasmid DNA, and by genetically engineered cells with different pharmacokinetic and physiological properties. In the present study, we examined a new method for delivery of rVEGF using implantable bioartificial muscle (BAM) tissues made from genetically modified primary skeletal myoblasts. Our goal was to determine whether the rVEGF delivered by this technique promoted controlled angiogenesis in nonischemic and/or ischemic adult mouse tissue. Methods and Results Primary adult mouse myoblasts were retrovirally transduced to secrete human or mouse rVEGF and tissue-engineered into implantable 1×10 to 15-mm BAMs containing parallel arrays of postmitotic myofibers. In vitro, they secreted 290 to 511 ng of bioactive mouse or human VEGF/BAM per day. rVEGF BAMs implanted subcutaneously into syngeneic mice caused a 30-fold increase in the number of CD31-positive capillary cells within the BAM by 1 week compared with control BAMs. Implantation of rVEGF-secreting BAMs into ischemic hindlimbs resulted in a 2- to 3-fold increase in capillary density of neighboring host muscle by 1 week and out to 4 weeks with no evidence of hemangioma formation. Conclusions Local delivery of rVEGF from BAMs rapidly increases capillary density both within the BAM itself and in adjacent ischemic muscle tissue. Genetically engineered muscle tissue provides a method for therapeutic protein delivery in a dose-regulated fashion.Keywords
This publication has 17 references indexed in Scilit:
- Cardiovascular gene therapyThe Lancet, 2000
- Focal angiogen therapy using intramyocardial delivery of an adenovirus vector coding for vascular endothelial growth factor 121 1 1Ronald G. Crystal and Todd K. Rosengart contributed equally as senior investigators in this study.The Annals of Thoracic Surgery, 2000
- Tissue-Engineered Human Bioartificial Muscles Expressing a Foreign Recombinant Protein for Gene TherapyHuman Gene Therapy, 1999
- Attenuation of Skeletal Muscle Wasting with Recombinant Human Growth Hormone Secreted from a Tissue-Engineered Bioartificial MuscleHuman Gene Therapy, 1998
- Vascular Endothelial Growth Factor-C (VEGF-C/VEGF-2) Promotes Angiogenesis in the Setting of Tissue IschemiaThe American Journal of Pathology, 1998
- Tissue-Engineered Skeletal Muscle Organoids for Reversible Gene TherapyHuman Gene Therapy, 1996
- Prolonged Expression of Therapeutic Levels of Human Granulocyte Colony-Stimulating Factor in Rats Following Gene Transfer to Skeletal MuscleHuman Gene Therapy, 1996
- Adenoviruses as Gene-Delivery VehiclesNew England Journal of Medicine, 1996
- Clinical Applications of Research on AngiogenesisNew England Journal of Medicine, 1995
- Systemic Delivery of Human Growth Hormone by Injection of Genetically Engineered MyoblastsScience, 1991